ABT-767 / AbbVie - LARVOL DELTA

Population pharmacokinetics of ABT-767 in BRCA1 or BRCA2 mutation carriers with advanced solid tumors or in subjects with high grade serous ovarian, primary peritoneal or fallopian tube cancer. (PubMed) - Cancer Chemother Pharmacol - "Albumin on CL/F was the only statistically significant baseline covariate affecting ABT-767 pharmacokinetics, but it only explained a fraction of the pharmacokinetic variability. Dosage adjustments based on body size, age, or mild renal impairment are not needed for ABT-767. The developed model will be used to evaluate ABT-767 exposure-response analyses and to perform simulations for different dose and dosing regimens."

Journal • Biosimilar • Gynecologic Cancers • Oncology • Renal Disease

A phase 1 study of PARP-inhibitor ABT-767 in advanced solid tumors with BRCA1/2 mutations and high-grade serous ovarian, fallopian tube, or primary peritoneal cancer. (PubMed, Invest New Drugs) - "Conclusions ABT-767 had an acceptable safety profile up to the established RP2D of 400 mg BID and dose-proportional PK. Patients with BRCA1 or BRCA2 mutation, HRD positivity, and platinum sensitivity were more sensitive to ABT-767."

Biomarker • BRCA Biomarker • Journal • P1 data • PARP Biomarker

53BP1 as a potential predictor of response in PARP inhibitor-treated homologous recombination-deficient ovarian cancer. (PubMed, Gynecol Oncol) - "Differences in complementary repair pathways, particularly 53BP1, correlate with PARPi response of HR-deficient ovarian cancers."

BRCA Biomarker • Journal • PARP Biomarker